This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

SBU’s appraisal of the evidence;
Monthly treatment with ranibizumab has a substantial inhibitory effect on the course of disease compared to photodynamic therapy or sham injection in patients with neovascular age-related macular degeneration – in followup ≤2 years (Evidence Grade 1)*.
Monthly treatment improves vision to a substantially higher degree in patients treated with ranibizumab compared to those who received photodynamic therapy or sham injection – in followup ≤2 years (Evidence Grade 1)*.
Scientific evidence is insufficient* regarding the effects of treatment when delivered less frequently than once per month, or for periods exceeding 2 years.
It is unclear whether treatment can be discontinued, or if further treatments are necessary to maintain the effects (Insufficient Scientific Evidence)*.
Scientific evidence is insufficient* to assess the cost-effectiveness of the method.

http://www.inahta.org/Publications/Briefs-Checklist-Impact/2009/4028/